Diabetes Clinical Trial
Official title:
Evaluation of the Tubular Effects of Dapagliflozin Using 1HNMR Spectroscopy
This is a phase IV study that will explore the mechanisms of action of a drug (dapagliflozin) that is already commercially available in the country where the study will be conducted (Greece). The drug will be used according to its approved clinical indications (as add-on treatment in patients failed to achieve glycemic targets on metformin monotherapy) and in the approved posology (10 mg/day). Additionally, although there is limited data on the coadministration of dapagliflozin with thiazides, the excellent safety profile of the drug even when it is used in combination with drugs that induce significant volume depletion (such as loop diuretics) suggests that, in properly selected patients, the possibility of important adverse events during the coadministration of dapagliflozin with chlorthalidone is very low. All patients will give written informed consent prior to their enrollment in the study. The study protocol will be approved by the scientific committee of the University Hospital of Ioannina.
Fifty patients with type 2 diabetes on metformin monotherapy with HbA1c > 7% and blood
pressure > 140/90 mmHg will be included. All eligible patients will be given dapagliflozin 10
mg qd for 3 months. Routine laboratory parameters that will be measured on each visit
include: 1) for serum samples: glucose, urea, creatinine, uric acid, electrolytes (sodium,
potassium, chloride, calcium, phosphate and magnesium and 2) for urine samples: glucose,
urea, creatinine, uric acid, electrolytes (sodium, potassium, chloride, calcium, phosphate
and magnesium) and alpha-1 microglobulin. It is well known that alpha-1 microglobulin is a
low-molecular weight protein that is normally filtered by renal glomeruli and reabsorbed by
the proximal tubular cells. Increased excretion of alpha1-microglobulin has been proposed as
a non-invasive marker for the diagnosis and monitoring of early tubular disorders such as
diabetic nephropathy. In addition, the fractional excretion values (FE) of the electrolytes
will be calculated using the formula: FEA(%) = (UrineA/SerumA) /(UrineCr/SerumCr) × 100.
The 1HΝMR spectra of urine samples will be recorded on a 500 MHz spectrometer. In the present
study, the main low molecular weight (LMW) constituents of urine that will be quantified are
1) metabolites such as glucose, creatinine, creatine, choline, taurine, dimethylamine,
betaine, trimethylaminoxide 2) amino acids such as glycine, valine, alanine, leucine,
histidine, lysine, threonine and 3) organic acids such as citrate, hippurate, lactate,
acetate, succinate, and formate. In addition, 1HNMR methodology allows for the detection of
changes in the concentrations of hundreds of metabolites. These substances are normally
present in traces, whereas in pathological conditions their concentrations can be found
increased.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05594446 -
Morphometric Study of the Legs and Feet of Diabetic Patients in Order to Collect Data Intended to be Used to Measure by Dynamometry the Pressures Exerted by Several Medical Compression Socks at the Level of the Forefoot
|
||
Completed |
NCT03975309 -
DHS MIND Metabolomics
|
||
Completed |
NCT01855399 -
Technologically Enhanced Coaching: A Program to Improve Diabetes Outcomes
|
N/A | |
Completed |
NCT01819129 -
Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes
|
Phase 3 | |
Recruiting |
NCT04984226 -
Sodium Bicarbonate and Mitochondrial Energetics in Persons With CKD
|
Phase 2 | |
Recruiting |
NCT05007990 -
Caregiving Networks Across Disease Context and the Life Course
|
||
Active, not recruiting |
NCT04420936 -
Pragmatic Research in Healthcare Settings to Improve Diabetes and Obesity Prevention and Care for Our Program
|
N/A | |
Recruiting |
NCT03549559 -
Imaging Histone Deacetylase in the Heart
|
N/A | |
Completed |
NCT04903496 -
Clinical Characteristics and Disease Burden of Diabetic Patients Based on Tianjin Regional Database
|
||
Completed |
NCT01437592 -
Investigating the Pharmacokinetic Properties of NN1250 in Healthy Chinese Subjects
|
Phase 1 | |
Completed |
NCT01696266 -
An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
|
||
Completed |
NCT04082585 -
Total Health Improvement Program Research Project
|
||
Completed |
NCT03390179 -
Hyperglycemic Response and Steroid Administration After Surgery (DexGlySurgery)
|
||
Not yet recruiting |
NCT05029804 -
Effect of Walking Exercise Training on Adherence to Disease Management and Metabolic Control in Diabetes
|
N/A | |
Recruiting |
NCT05294822 -
Autologous Regenerative Islet Transplantation for Insulin-dependent Diabetes
|
N/A | |
Completed |
NCT04427982 -
Dance and Diabetes/Prediabetes Self-Management
|
N/A | |
Completed |
NCT02356848 -
STEP UP to Avert Amputation in Diabetes
|
N/A | |
Completed |
NCT03292185 -
A Trial to Investigate the Single Dose Pharmacokinetics of Insulin Degludec/Liraglutide Compared With Insulin Degludec and Liraglutide in Healthy Chinese Subjects
|
Phase 1 | |
Active, not recruiting |
NCT05477368 -
Examining the Feasibility of Prolonged Ketone Supplement Drink Consumption in Adults With Type 2 Diabetes
|
N/A | |
Completed |
NCT04496401 -
PK Study in Diabetic Transplant récipients : From Twice-daily Tacrolimus to Once-daily Extended-release Tacrolimus
|
Phase 4 |